Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 22 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-4.00 Insider Own18.14% Shs Outstand2.58M Perf Week-9.43%
Market Cap28.48M Forward P/E- EPS next Y-6.45 Insider Trans-56.55% Shs Float2.12M Perf Month6.56%
Income-35.94M PEG- EPS next Q-2.82 Inst Own10.83% Short Float5.13% Perf Quarter-25.15%
Sales0.68M P/S41.89 EPS this Y-13.19% Inst Trans-70.17% Short Ratio0.92 Perf Half Y-33.09%
Book/sh-1.59 P/B- EPS next Y58.58% ROA-126.53% Short Interest0.11M Perf Year-12.21%
Cash/sh6.89 P/C1.60 EPS next 5Y- ROE-946.56% 52W Range8.44 - 37.00 Perf YTD-5.52%
Dividend Est.- P/FCF- EPS past 5Y14.48% ROI- 52W High-70.16% Beta0.37
Dividend TTM- Quick Ratio0.82 Sales past 5Y-25.00% Gross Margin84.00% 52W Low30.73% ATR (14)1.06
Dividend Ex-Date- Current Ratio0.82 EPS Y/Y TTM-626.20% Oper. Margin-5032.44% RSI (14)49.91 Volatility9.32% 9.70%
Employees15 Debt/Eq- Sales Y/Y TTM-76.55% Profit Margin-5324.59% Recom1.00 Target Price73.33
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q-1347.24% Payout- Rel Volume0.66 Prev Close10.84
Sales Surprise- EPS Surprise-5.41% Sales Q/Q-100.00% EarningsNov 13 AMC Avg Volume118.44K Price11.04
SMA202.13% SMA500.71% SMA200-29.72% Trades Volume77,745 Change1.85%
Date Action Analyst Rating Change Price Target Change
Jan-25-22Downgrade Stifel Buy → Hold $20 → $6.20
Nov-09-21Upgrade Stifel Hold → Buy $20
Oct-12-21Initiated Credit Suisse Outperform $20
Oct-04-21Initiated Mizuho Buy $20
Sep-21-21Initiated JMP Securities Mkt Outperform $33
Sep-20-21Initiated Stifel Hold $20
Sep-13-21Initiated Cantor Fitzgerald Overweight $50
Feb-05-24 08:30AM
Jan-30-24 09:55AM
Jan-29-24 04:05PM
Jan-25-24 08:00AM
Jan-09-24 08:05AM
08:00AM Loading…
Dec-08-23 08:15AM
Nov-28-23 08:00AM
Nov-15-23 08:00AM
Nov-13-23 04:14PM
Nov-06-23 08:00AM
Oct-24-23 08:00AM
Sep-11-23 08:00AM
Aug-30-23 08:00AM
Aug-11-23 06:05AM
04:01PM Loading…
Aug-08-23 04:01PM
Jun-08-23 04:01PM
Jun-07-23 08:00AM
May-31-23 05:43PM
May-26-23 09:00AM
May-25-23 04:50PM
May-09-23 04:01PM
May-08-23 08:00AM
Apr-26-23 04:01PM
Apr-11-23 08:00AM
Mar-28-23 08:30AM
Mar-08-23 04:01PM
Feb-21-23 08:30AM
Jan-30-23 08:00AM
Jan-05-23 04:01PM
04:00PM Loading…
Nov-07-22 04:00PM
Oct-31-22 02:05PM
Oct-26-22 08:00AM
Sep-26-22 08:00AM
Sep-21-22 09:00AM
Sep-14-22 08:00AM
Sep-06-22 08:30AM
Aug-09-22 04:01PM
Aug-08-22 05:30AM
Jun-07-22 08:00AM
Jun-05-22 05:00PM
May-26-22 05:15PM
May-10-22 04:02PM
May-03-22 06:45AM
May-02-22 04:04PM
Apr-04-22 08:30AM
Mar-16-22 04:01PM
Feb-16-22 08:30AM
Feb-15-22 06:53PM
Feb-09-22 04:00PM
Jan-24-22 04:00PM
Nov-24-21 08:00AM
Nov-22-21 08:00AM
Nov-08-21 07:00AM
Nov-04-21 09:08AM
Nov-01-21 04:05PM
Oct-26-21 08:00AM
Oct-07-21 04:30PM
Sep-30-21 04:32PM
Sep-16-21 08:00AM
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). Its STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The company was founded by Kevan Shokat, Davide Ruggero, and Siegfried Reich on May 1, 2012 and is headquartered in Solana Beach, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SR ONE CAPITAL MANAGEMENT, LLC10% OwnerNov 27Sale0.61609,163369,4571,821,415Nov 29 05:07 PM
WORLAND STEPHEN TChief Executive OfficerAug 11Option Exercise0.5233,79917,575261,225Aug 14 08:00 AM